ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Conversation with The Cancer Letter: McKinsey Charge: Create Plan To Expand MD Anderson’s Reach

February 7, 2014

ASCO Annual Meeting Attendance Tops 25,000, Continuing Fast Growth.

May 18, 2001

Clinical Research: Cooperative Groups Form Coalition to Advance Trials

November 14, 1997

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

July 27, 2007

DCE Board Approves concepts For Grants to Develop HPV Animal Models, ALL Etiology Contracts

March 11, 1988